- Home
- ESNT vs RVPH Comparison
ESNT vs RVPH Comparison
Compare ESNT & RVPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESNT
- RVPH
- Stock Information
- Founded
- ESNT 2008
- RVPH 2006
- Country
- ESNT Bermuda
- RVPH United States
- Employees
- ESNT N/A
- RVPH N/A
- Industry
- ESNT Property-Casualty Insurers
- RVPH Biotechnology: Pharmaceutical Preparations
- Sector
- ESNT Finance
- RVPH Health Care
- Exchange
- ESNT Nasdaq
- RVPH Nasdaq
- Market Cap
- ESNT N/A
- RVPH 32.8M
- IPO Year
- ESNT 2013
- RVPH N/A
- Fundamental
- Price
- ESNT $55.73
- RVPH $0.39
- Analyst Decision
- ESNT Buy
- RVPH Strong Buy
- Analyst Count
- ESNT 7
- RVPH 5
- Target Price
- ESNT $63.71
- RVPH $9.00
- AVG Volume (30 Days)
- ESNT 775.5K
- RVPH 3.7M
- Earning Date
- ESNT 08-01-2025
- RVPH 08-13-2025
- Dividend Yield
- ESNT 2.22%
- RVPH N/A
- EPS Growth
- ESNT 3.49
- RVPH N/A
- EPS
- ESNT 6.84
- RVPH N/A
- Revenue
- ESNT $1,262,105,000.00
- RVPH N/A
- Revenue This Year
- ESNT $5.48
- RVPH N/A
- Revenue Next Year
- ESNT $3.59
- RVPH N/A
- P/E Ratio
- ESNT $8.16
- RVPH N/A
- Revenue Growth
- ESNT 9.57
- RVPH N/A
- 52 Week Low
- ESNT $51.61
- RVPH $0.30
- 52 Week High
- ESNT $65.34
- RVPH $4.28
- Technical
- Relative Strength Index (RSI)
- ESNT 34.41
- RVPH 35.22
- Support Level
- ESNT $55.80
- RVPH $0.38
- Resistance Level
- ESNT $56.68
- RVPH $0.45
- Average True Range (ATR)
- ESNT 1.02
- RVPH 0.05
- MACD
- ESNT -0.64
- RVPH 0.01
- Stochastic Oscillator
- ESNT 2.10
- RVPH 17.57
About RVPH Reviva Pharmaceuticals Holdings Inc.
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease and Parkinson's disease psychosis and its other drug candidate is RP1208.